BMO Capital downgrades Strategic Education stock rating on enrollment declines

BMO Capital downgraded Strategic Education to Market Perform from Outperform, setting a $66 price target, after Q3 2026 EPS of $1.72 missed the $1.95 estimate by 11.8%; revenue of $325.1 million was near expectations. The stock fell 19.86% over the past week and was trading at $58.47, near its 52-week low of $57.10. Enrollment and margin declines, a deteriorating regulatory environment, and the company’s 2027 investment-year outlook are expected to delay recovery, although BMO said the balance sheet and cash flow remain strong.

Analysis

The key issue is earnings power, not demand alone: revenue tracking expectations alongside an EPS miss raises the question of whether enrollment mix, Australia/New Zealand margins, and planned growth investment are eroding conversion of sales into profit. The impairment complicates the read-through; separate its accounting effect from recurring operating-margin deterioration before treating the miss as a new run rate. A 2027 investment year also shifts the payoff from growth initiatives out while leaving near-term execution and regulatory risk in the P&L. Strong cash flow and balance-sheet commentary may limit financing risk, but does not establish that the shares are cheap; the cited fair-value assessment is not independent evidence of a floor.

Near term, the sharp repricing and proximity to the $57.10 52-week low create scope for a relief bounce, but the delayed recovery weakens the case for buying solely on valuation. Over 1–3 months, enrollment trends, underlying margins excluding impairment, and any update to 2027 investment or regulatory assumptions are the decisive catalysts. Over 6–18 months, successful execution in healthcare, employer-affiliated programs, ETS, and domestic Australia could restore growth, but spending ahead of returns could prolong margin pressure. The downside thesis weakens if enrollment stabilizes and recurring margins recover; a sustained break below the recent low alongside weaker guidance would reinforce it.

Key Decisions for Investors

• Avoid initiating a full-sized dip-buy in STRA here; wait for evidence of stabilization in enrollment and recurring margins, rather than relying on the third-party fair-value claim.
• For existing exposure, size risk around the $57.10 low and reassess on a sustained break below it; do not treat that level as guaranteed support. A recovery in underlying margins and enrollment would invalidate a bearish breakdown thesis.
• Watch the next results and guidance for enrollment by geography, margin performance excluding the Australia impairment, and returns on 2027 growth investment. If these data are not disclosed clearly, keep the position small rather than inferring a recovery from headline revenue.
• The late downgrade and steep weekly decline make a fresh outright short less attractive without confirmation. Revisit a tactical short only if the stock fails to stabilize and guidance or enrollment evidence deteriorates further.